Skip to main content
. 2014 Jun 18;7:1083–1094. doi: 10.2147/OTT.S64759

Figure 2.

Figure 2

DFS curves of high or low ID2 expression according to breast cancer subtypes: luminal-A (A), luminal-B (B), HER-2+ (C), and triple-negative (D). The prognostic value of ID2 was most significant for DFS, among patients with TNBC, (P=0.009).

Abbreviations: DFS, disease-free survival; HER-2, human epidermal growth factor receptor 2; ID, inhibitor of DNA-binding; TNBC, triple negative breast cancer.